DENGUE

This study tests a dengue vaccine in adults aged 60 to 79 and compares their immune response and safety to adults aged 40 to 59. About 997 healthy participants will receive one dose of the Butantan dengue vaccine. The goal is to see if the vaccine works as well in older adults as…

This study tests a new medicine called CP-COV03 in adults with dengue fever. The goal is to see if it can safely lower the amount of virus in the blood and help people feel better faster. About 210 participants will receive either the drug or a placebo. The trial is currently rec…

This phase 2 trial is testing two antivirals—molnupiravir (used for COVID-19) and a lab-made antibody called VIS513—in 500 people with early dengue. Participants must have had fever for less than 48 hours and a positive rapid test. The goal is to see if these drugs can clear the …

This Phase 2 trial tests an experimental drug called EYU688 in 108 adults with dengue fever. Participants receive either the drug or a placebo to see if it lowers the amount of virus in the blood and shortens fever. The study is currently recruiting.

This study involves giving a weakened dengue virus to 5 healthy adults aged 21-45 in Singapore to safely study how the body fights the infection. The goal is to create a reliable model for testing future dengue vaccines and treatments. Participants will be closely monitored for s…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study follows 100 people with confirmed dengue to identify which symptoms and lab results predict hospitalization. It also tracks how often blood transfusions are given and their outcomes. The goal is to improve care for dengue patients, not to test a new treatment.